Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 1—January 2008
Dispatch

Adamantane-Resistant Influenza Infection During the 2004–05 Season

Mahbubur Rahman*1, Rick A. Bright†2, Burney A. Kieke*, James G. Donahue*, Robert T. Greenlee*, Mary Vandermause*, Amanda Balish†, Angela Foust†, Nancy J. Cox†, Alexander I. Klimov†, David K. Shay†, and Edward A. Belongia*Comments to Author 
Author affiliations: *Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 1

Clinical features of patients with adamantane-resistant or -susceptible influenza A, 2004–05 season

Clinical featureAdamantane-resistant influenza, n = 72Adamantane-susceptible influenza, n = 80p value*
Median duration of illness†12 days13 days0.96
No. (%) hospitalized7 (10)9 (12)0.74
No. (%) fully recovered at time of follow-up interview63 (88)65 (81)0.29
Median no. symptoms‡980.59
No. (%) receiving antiviral treatment§15 (21)31 (39)0.02
Median time from symptom onset to healthcare encounter
3 days
2 days
0.34
Single symptom, no. (%)‡
Fever34 (69)52 (74)0.56
Cough48 (98)68 (97)0.78
Headache41 (84)53 (76)0.29
Muscle pain37 (76)45 (64)0.57
Nasal congestion40 (82)54 (77)0.55
Hoarseness35 (71)55 (79)0.37
Fatigue45 (92)66 (94)0.72
Ear pain16 (33)24 (34)0.85
Sore throat29 (59)40 (57)0.82
Difficulty breathing28 (57)35 (50)0.44
Wheezing25 (51)42 (60)0.33
Nausea16 (33)27 (39)0.51
Vomiting10 (20)9 (13)0.27
Diarrhea12 (24)15 (21)0.70
Rash
2 (4)
2 (3)
1.00
Combined symptoms, no. (%)‡
Fever and cough33 (67)52 (74)0.41
Fever and headache31 (63)43 (61)0.84
Fever, cough, and headache30 (61)43 (61)0.98
Fever and muscle pain29 (59)39 (56)0.71
Fever, headache, and muscle pain27 (55)35 (50)0.58
Fever, headache, muscle pain, and cough26 (53)35 (50)0.74

2, Fisher exact, or Wilcoxon rank sum tests performed as appropriate.
†Based on 128 influenza A patients who had recovered fully at the time of follow-up interview.
‡Children 6 to 23 months of age were excluded from the numerator and denominator for symptoms.
§One patient had received antiviral treatment prior to influenza culture.

Main Article

1Current affiliation: University of Texas Medical Branch, Galveston, Texas, USA

2Current affiliation: Novavax, Malvern, Pennsylvania, USA

Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external